Approval · Notice of Compliance 32099 · 2023
OZEMPIC: Notice of Compliance 32099
Issued November 15, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32099
- Date
- November 15, 2023
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site for the drug product. Changes to the manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OZEMPIC | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 2.68 MG per ML